A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether dasatinib is effective and safe in the
treatment of refractory metastatic gastrointestinal stromal tumor